Cortical Blindness:Etiology, Diagnosis, & Prognosis
Ann Neurol 21:149-158, Aldrich,M.S.,et al, 1987
Neurosarcoidosis:Signs, Course and Treatment in 35 Confirmed Cases
Medicine 69:261-276, Chapelon,C.,et al, 1990
Central Achromatopsia:Behavioral, Anatomic, & Physiologic Aspects
Neurol 30:1064-1071, Damasio,A.,et al, 1980
Association Between Clinical Conversion to Multiple Sclerosis in Radiologically Isolated Syndrome and Magnetic Resonance Imaging, Cerebrospinal Fluid, and Visual Evoked Potential: Follow-Up of 70 Patients
Arch Neurol 66:841-846, Lebrun,C.,et al, 2009
Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
Ann Neurol 50:121-127, McDonald,W.I.,et al, 2001
New Diagnostic Criteria for Multiple Sclerosis:Guidelines for Research Protocols
Neurol 13:227-231, Poser,C.M.,et al, 1983
Carotid Occlusive Disease, Effect of Bright Light on Visual Evoked Response
Arch Neurol 39:687-689, Donnan,G.A.,et al, 1982
Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017
Early Visual Function Impairment in CADASIL
Neurol 60:2008-2010, Parisi,V.,et al, 2003
Practice Parameter: The Usefulness of Evoked Potentials in Identifying Clinically Silent Lesions in Patients With Suspected Multiple Sclerosis (an Evidence-Based Review)
Neurol 54:1720-1725, Gronseth,G.S.&Ashman,E.J., 2000
Infantile Neuroaxonal Dystrophy,Clinical Spectrum and Diagnostic Criteria
Neurol 52:1472-1478, Nardocci,N.,et al, 1999
A Man Who Lost Weight and His Sight
Lancet 351:1174-1175, Moschos,M.&Droutsas,D., 1998
Visual Evoked Potential in Adrenoleukodystrophy:Glycerol Trioleate and Lorenzo Oil
Ann Neurol 34:169-174, 1211993., Kaplan,P.W.,et al, 1993
Intra-arterial Cisplatin-Associated Optic and Otic Toxicity
Arch Neurol 49:83-86, Maiese,K.,et al, 1992
Evoked Potentials in Cerebrotendinous Xanthomatosis and Effect Induced by Chenodeoxycholic Acid
Arch Neurol 49:469-475, Mondelli,M.,et al, 1992
Effects of Intravent Hemorrhage & Socioecon Status on NEur Status of Low Birth Weight Inf at 5 yrs of age
J Pediatr 121:280-285, Vohr,B.,et al, 1992
Lidocaine Unmasks Silent Demyelinative Lesions in Multiple Sclerosis
Neurol 42:2088-2093, Sakurai,M.,et al, 1992
Longitudinal Neurophysiologic Studies in Pt with Metachromatic Leukodystrophy Following Bone Marrow Trnspl
Arch Neurol 49:1088-1092, Dhuna,A.,et al, 1992
Reversal of a Neurologic Paraneoplastic Syndrome with Octreotide (Sandostatin) in a Pt with Glucagonoma
Am J Med 91:434-436, Holmes,A.,et al, 1991
Infantile CNS Spongy Degeneration-14 Cases:Clinical Update
Neurol 40:1876-1882, Gascon,G.G.,et al, 1990
Visual & Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions
NEJM 314:869-873, Olivieri,N.F.,et al, 1986
The Value of Visual Evoked Potential as a Screening Test in Neurofibromatosis
Arch Neurol 42:1072-1074, Jabbari,B.,et al, 1985
Evoked Potentials In Clinical Medicine, (First of Two Parts)
NEJM 306:1140-1150, Chiappa,K.H.,et al, 1982
Visual Evoked Potentials in Occipital Lobe Lesions
Arch Neurol 38:80-85, Streletz,L.J.,et al, 1981
Visual Function of the Extrageniculo-calcarine System in Man
Arch Neurol 37:704-706, Celesia,G.G.,et al, 1980
Visual Evoked Potentials in Infants with Hydrocephalus
Neurol 29:1541-1544, Ehle,A.,et al, 1979
Visual Evoked Potentials in the Evaluation of"Cortical Blindness"in Children
Ann Neurol 6:126-129, Frank,Y.,et al, 1979
Toluene Optic Neuropathy
Ann Neurol 4:390, Keane,J.R., 1978
Subclinical Optic Neuropathy in Multiple Sclerosis
Arch Neurol 34:666, Galvin,R.J.,et al, 1977